Both ERBB2 mutants cooperated with p53 loss and gave rise to GBC with a median OS of 79.5 and 58.5 days for ERBB2S310F and ERBB2V777L, respectively, whereas wildtype ERBB2 unexpectedly did not lead to tumor development within the observational period of four months (Figure 4C,D). The gene discussed is TP53; the disease is neoplasm.